



Consolidated Financial Results for the Fiscal Year Ended February 28, 2026 [Japanese GAAP]

April 13, 2026

Company name: Hisamitsu Pharmaceutical Co., Inc.
 Stock exchange listing: Tokyo, Nagoya, Fukuoka
 Securities code: 4530
 URL: <https://global.hisamitsu/>
 Representative: NAKATOMI Kazuhide, President & CEO
 Contact: ISOBE Yuichi, Director, Executive Officer Head of Corporate Strategy Planning Division
 TEL: +81-3-5293-1704
 Scheduled date of Annual General Meeting of Shareholders: May 28 2026
 Scheduled date of dividend payment: —
 Scheduled date of filing annual securities report: —
 Preparation of supplementary materials for financial results: No
 Holding of annual financial results meeting: No

(Amounts are rounded down to the nearest millions of yen)

1. Consolidated Financial Results for the Fiscal Year Ended February 28, 2026 (March 1, 2025 to February 28, 2026)

(1) Consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year 2026	163,024	4.5	17,917	(5.2)	23,952	(0.2)	19,160	(11.9)
Fiscal year 2025	156,006	10.1	18,895	43.5	24,010	22.2	21,758	55.8

(Note) Comprehensive income: Fiscal year 2026 33,415 millions of yen (13.1%)
 Fiscal year 2025 29,546 millions of yen (14.8%)

	Profit per share	Diluted profit per share	Return on equity	Ordinary profit on total assets	Operating profit to net sales
	Yen	yen	%	%	%
Fiscal year 2026	268.56	268.22	6.7	6.7	11.0
Fiscal year 2025	295.57	295.15	8.0	7.1	12.1

(Reference) Share of profit (loss) of entities accounted for using equity method: Fiscal year 2026 728 millions of yen
 Fiscal year 2025 590 millions of yen

(2) Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Fiscal year 2026	367,162	294,694	79.4	4,140.19
Fiscal year 2025	343,068	279,407	80.6	3,788.47

(Reference) Shareholders' equity: Fiscal year 2026 291,476 millions of yen
 Fiscal year 2025 276,417 millions of yen

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year 2026	17,478	(16,866)	(20,198)	69,931
Fiscal year 2025	18,765	17,563	(15,850)	89,780

2. Dividends

	Annual dividends					Total dividends	Payout ratio (consolidated)	Dividends to net assets (consolidate)
	First quarter	Second quarter	Third quarter	Fourth quarter	Total			
	yen	yen	yen	yen	yen	Millions of yen	%	%
Fiscal year 2025	—	45.00	—	45.00	90.00	6,603	30.4	2.5
Fiscal year 2026		60.00		0.00	60.00	4,288	22.3	1.5
Fiscal year 2027 (Forecast)	—	—	—	—	—		—	

(Note): Notice Regarding Results of Tender Offer for Shares, Etc. of Hisamitsu Pharmaceutical Co., Inc. by TAIYO KOSAN CO., INC. and Change in Parent Company, the Largest Shareholder that is a Major Shareholder, and Major Shareholder” dated February 20, 2026, as a result of the Offeror’s tender offer for ordinary shares of the Company and the American Depositary Receipts and a series of subsequent transactions, the Company’s shares are scheduled to be delisted on May 11, 2026. Therefore, cash dividends forecast for the fiscal year ending February 28, 2027 is not provided.

3. Consolidated Earnings Forecast for the Fiscal Year Ended February 28, 2027 (March 1, 2026 to February 28, 2027)

Notice Regarding Results of Tender Offer for Shares, Etc. of Hisamitsu Pharmaceutical Co., Inc. by TAIYO KOSAN CO., INC. and Change in Parent Company, the Largest Shareholder that is a Major Shareholder, and Major Shareholder” dated February 20, 2026, as a result of the Offeror’s tender offer for ordinary shares of the Company and the American Depositary Receipts and a series of subsequent transactions, the Company’s shares are scheduled to be delisted on May 11, 2026. Therefore, consolidated earnings forecast for the fiscal year ending February 28, 2027 is not provided.

*Notes

(1) Changes in significant subsidiaries during the period
(Changes in specified subsidiaries resulting in changes in scope of consolidation) : None

(2) Changes in accounting policies, changes in accounting estimates, and restatement
 1) Changes in accounting policies due to revision of accounting standards : Yes
 2) Changes in accounting policies other than 1) above : None
 3) Changes in accounting estimates : None
 4) Restatement : None

(3) The number of shares outstanding (common stock)
 1) Total number of shares outstanding at the end of the period (including treasury stock)
 Fiscal year 2026: 75,164,895 shares
 Fiscal year 2025: 85,164,895 shares

2) Total number of treasury stock at the end of the period
 Fiscal year 2026: 4,763,348 shares
 Fiscal year 2025: 12,202,127 shares

3) Average number of shares outstanding during the period
 Fiscal year 2026: 71,346,040 shares
 Fiscal year 2025: 73,612,670 shares

(Note) The Company’s shares held by the “HISAMITSU PHARMACEUTICAL Employee Stockholding Partnership Plan Trust Account” are included in the treasury stock deduction in the calculation of the average number of shares during the period (301,033 shares for the fiscal year ended Feb.28, 2026).

Consolidated Financial Statements

(1) Consolidated Balance sheets

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2025)	Current Fiscal Year End (As of Feb. 28, 2026)
Assets		
Current assets		
Cash and deposits	114,518	108,859
Notes and accounts receivable - trade, and contract assets	47,223	56,584
Securities	14,598	9,779
Merchandise and finished goods	12,044	13,971
Work in process	794	1,040
Raw materials and supplies	9,553	10,905
Other	5,400	5,031
Allowance for doubtful accounts	(344)	(262)
Total current assets	203,788	205,909
Non-current assets		
Property, plant and equipment		
Buildings and structures	67,659	71,146
Accumulated depreciation	(38,614)	(40,236)
Buildings and structures, net	29,045	30,910
Machinery, equipment and vehicles	49,577	52,087
Accumulated depreciation	(41,234)	(42,446)
Machinery, equipment and vehicles, net	8,342	9,640
Tools, furniture and fixtures	13,391	13,369
Accumulated depreciation	(9,461)	(10,011)
Tools, furniture and fixtures, net	3,930	3,358
Land	11,703	11,576
Leased assets	1,776	2,056
Accumulated depreciation	(684)	(615)
Leased assets, net	1,092	1,441
Construction in progress	5,786	3,593
Total property, plant and equipment	59,899	60,519
Intangible assets		
Sales rights	300	255
Software	204	279
Goodwill	1,294	1,143
Other	4,175	3,702
Total intangible assets	5,974	5,380
Investments and other assets		
Investment securities	60,222	80,668
Net defined benefit asset	7,439	9,062
Deferred tax assets	1,911	2,357
Other	4,038	3,471
Allowance for doubtful accounts	(207)	(207)
Total investments and other assets	73,405	95,353
Total non-current assets	139,280	161,253
Total assets	343,068	367,162

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2025)	Current Fiscal Year End (As of Feb. 28, 2026)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	9,910	11,245
Electronically recorded obligations - operating	4,205	5,971
Short-term loans payable	1,065	907
Lease obligations	409	344
Accounts payable - other	8,152	10,039
Income taxes payable	3,627	1,808
Provision for bonuses	2,213	2,422
Contract liabilities	2,864	1,202
Other	14,776	16,475
Total current liabilities	47,226	50,418
Non-current liabilities		
Long-term loans payable	1,694	—
Lease obligations	688	1,124
Deferred tax liabilities for land revaluation	1,646	1,694
Deferred tax liabilities	2,658	9,887
Net defined benefit liability	7,819	7,575
Other	1,926	1,767
Total non-current liabilities	16,434	22,048
Total liabilities	63,661	72,467
Net assets		
Shareholders' equity		
Capital stock	8,473	8,473
Capital surplus	2,361	2,356
Retained earnings	257,881	230,653
Treasury shares	(47,550)	(19,127)
Total shareholders' equity	221,166	222,356
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	18,485	32,225
Revaluation reserve for land	3,337	3,288
Foreign currency translation adjustment	31,334	30,756
Remeasurements of defined benefit plans	2,093	2,848
Total accumulated other comprehensive income	55,250	69,119
Share acquisition rights	408	344
Non-controlling interests	2,581	2,874
Total net assets	279,407	294,694
Total liabilities and net assets	343,068	367,162

(2) Consolidated Statements of Income and Comprehensive Income

Consolidated Statements of Income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – Feb. 28, 2025)	Current Fiscal Year (Mar. 1, 2025 – Feb. 28, 2026)
Net sales	156,006	163,024
Cost of sales	64,810	66,903
Gross profit	91,196	96,121
Selling, general and administrative expenses	72,300	78,203
Operating profit	18,895	17,917
Non-operating income		
Interest income	2,748	2,360
Dividend income	1,245	1,282
Foreign exchange gains	—	935
Share of profit of entities accounted for using equity method	590	728
Other	782	861
Total non-operating income	5,365	6,167
Non-operating expenses		
Interest expenses	23	21
Foreign exchange losses	176	—
Other	51	111
Total non-operating expenses	251	132
Ordinary profit	24,010	23,952
Extraordinary income		
Gain on disposal of non-current assets	24	5
Gain on sale of investment securities	5,019	137
Total extraordinary income	5,044	143
Extraordinary losses		
Loss on disposal of non-current assets	23	68
Impairment losses	343	—
Voluntary recall related expenses	—	370
Total extraordinary losses	367	439
Profit before income taxes	28,687	23,656
Income taxes - current	5,624	3,622
Income taxes - deferred	760	481
Total income taxes	6,385	4,104
Profit	22,301	19,552
Profit attributable to non-controlling interests	543	391
Profit attributable to owners of parent	21,758	19,160

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – Feb. 28, 2025)	Current Fiscal Year (Mar. 1, 2025 – Feb. 28, 2026)
Profit	22,301	19,552
Other comprehensive income		
Valuation difference on available-for-sale securities	(3,580)	13,695
Land Revaluation Reserve	—	(48)
Foreign currency translation adjustment	9,764	(606)
Remeasurements of defined benefit plans, net of tax	1,039	731
Share of other comprehensive income of entities accounted for using equity method	21	90
Total other comprehensive income	7,244	13,863
Comprehensive income	29,546	33,415
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	28,954	33,028
Comprehensive income attributable to non-controlling interests	592	386

(3) Consolidated Statements of Changes in Shareholders' Equity

For the Fiscal Year Ended February 28, 2025 (March 1, 2024 to February 28, 2025)

(Millions of yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at March 1, 2024	8,473	2,361	242,578	(36,993)	216,420
Changes in items during period					
Dividends of surplus			(6,522)		(6,522)
Profit attributable to owners of parent			21,758		21,758
Reversal of revaluation reserve for land			66		66
Purchase of treasury shares				(10,556)	(10,556)
Disposal of Treasury Shares					—
Cancellation of Treasury Shares					—
Net changes in items other than shareholders' equity					—
Total changes of items during period	—	—	15,302	(10,556)	4,745
Balance at February 28 2025	8,473	2,361	257,881	(47,550)	221,166

(Millions of yen)

	Accumulated other comprehensive income					Share acquisition rights	Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Revaluation reserve for land	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income			
Balance at March 1, 2024	22,052	3,403	21,621	1,042	48,120	334	2,205	267,082
Changes in items during period								
Dividends of surplus								(6,522)
Profit attributable to owners of parent								21,758
Reversal of revaluation reserve for land								66
Purchase of treasury shares								(10,556)
Disposal of Treasury Shares								—
Cancellation of Treasury Shares								—
Net changes in items other than shareholders' equity	(3,566)	(66)	9,713	1,050	7,129	73	375	7,579
Total changes of items during period	(3,566)	(66)	9,713	1,050	7,129	73	375	12,324
Balance at February 28, 2025	18,485	3,337	31,334	2,093	55,250	408	2,581	279,407

For the Fiscal Year Ended February 28, 2026 (March 1, 2025 to February 28, 2026)

(Millions of yen)

	Shareholders' equity				
	Capital stock	Capital surplus	Retained Earnings	Treasury shares	Total shareholders' equity
Balance at March 1, 2025	8,473	2,361	257,881	(47,550)	221,166
Changes in items during period					
Dividends of surplus			(7,590)		(7,590)
Profit attributable to owners of parent			19,160		19,160
Reversal of revaluation reserve for land					—
Purchase of treasury shares				(12,273)	(12,273)
Disposal of Treasury Shares		81		1,812	1,893
Cancellation of Treasury Shares		(86)	(38,797)	38,884	—
Net changes in items other than shareholders' equity					—
Total changes of items during period	—	(4)	(27,227)	(28,422)	1,190
Balance at February 28, 2026	8,473	2,356	230,653	(19,127)	222,356

(Millions of yen)

	Accumulated other comprehensive income					Share acquisition rights	Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Revaluation reserve for land	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income			
Balance at March 1, 2025	18,485	3,337	31,334	2,093	55,250	408	2,581	279,407
Changes in items during period								
Dividends of surplus								(7,590)
Profit attributable to owners of parent								19,160
Reversal of revaluation reserve for land								—
Purchase of treasury shares								(12,273)
Disposal of Treasury Shares								1,893
Cancellation of Treasury Shares								—
Net changes in items other than shareholders' equity	13,739	(48)	(578)	755	13,868	(63)	293	14,097
Total changes of items during period	13,739	(48)	(578)	755	13,868	(63)	293	15,287
Balance at February 28, 2026	32,225	3,288	30,756	2,848	69,119	344	2,874	294,694

(4) Consolidated Statements of Cash Flows
Year ended February 28, 2025 and February 28, 2026

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – Feb. 28, 2024)	Current Fiscal Year (Mar. 1, 2025 – Feb. 28, 2026)
Cash flows from operating activities		
Profit before income taxes	28,687	23,656
Depreciation	6,185	6,901
Impairment losses	343	—
Amortization of goodwill	150	150
Increase (decrease) in net defined benefit liability	(9)	129
Increase (decrease) in provision for bonuses	325	201
Increase (decrease) in allowance for doubtful accounts	83	(78)
Interest and dividend income	(3,993)	(3,642)
Interest expenses	23	21
Foreign exchange losses (gains)	(109)	(501)
Share of loss (profit) of entities accounted for using equity method	(590)	(728)
Loss (gain) on sales of investment securities	(5,019)	(137)
Loss (gain) on disposal of non-current assets	(1)	63
Decrease (increase) in notes and accounts receivable - trade	(2,525)	(9,177)
Decrease (increase) in inventories	(347)	(3,482)
Decrease (increase) in other current assets	(572)	203
Increase (decrease) in notes and accounts payable - trade	(2,642)	2,890
Increase (decrease) in contract liabilities	(1,675)	(947)
Increase (decrease) in other current liabilities	1,032	3,729
Other, net	(736)	(500)
Subtotal	18,610	18,753
Interest and dividend income received	4,467	3,940
Interest expenses paid	(25)	(21)
Income taxes paid	(4,279)	(5,099)
Payments of retirement benefits for directors (and other officers)	(7)	(95)
Net cash provided by (used in) operating activities	18,765	17,478

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2024 – Feb. 28, 2025)	Current Fiscal Year (Mar. 1, 2025 – Feb. 28, 2026)
Cash flows from investing activities		
Decrease (increase) in time deposits	23,557	(8,996)
Purchase of property, plant and equipment	(13,627)	(7,995)
Proceeds from sales of property, plant and equipment	154	311
Purchase of intangible assets	(147)	(55)
Decrease (increase) in short-term investment securities	24	(182)
Purchase of investment securities	(511)	(166)
Proceeds from sales and redemption of investment securities	8,111	217
Collection of loans receivable	1	1
Net cash provided by (used in) investing activities	17,563	(16,866)
Cash flows from financing activities		
Proceeds from long-term borrowings	1,830	—
Increase (decrease) in short-term loans payable	—	(100)
Repayments of long-term loans payable	(217)	(1,752)
Dividends paid to non-controlling interests	(216)	(93)
Purchase of treasury shares	(10,554)	(12,273)
Cash dividends paid	(6,519)	(7,593)
Proceeds From Sales Of Treasury Stock	—	1,766
Other, net	(172)	(151)
Net cash provided by (used in) financing activities	(15,850)	(20,198)
Effect of exchange rate change on cash and cash equivalents	2,936	(262)
Net increase (decrease) in cash and cash equivalents	23,414	(19,849)
Cash and cash equivalents at beginning of period	66,366	89,780
Cash and cash equivalents at end of period	89,780	69,931



Promoting “TE-A-TE” Culture Worldwide

「手当て」の文化を、世界へ。

